TMED Fees and Costs — T. Rowe Price Health Care ETF
Data updated: 2026-08-27
The net expense ratio is 0.44%. There are no sales loads or redemption fees. Portfolio turnover was 44%.
TMED Fees and Expenses
Annual operating expenses and sales charges of TMED. Prospectus, as of February 25, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.44% |
| 12b-1 fee | — |
| Other expenses | 0.00% |
| Gross expense ratio | 0.44% |
| Fee waiver | — |
| Net expense ratio | 0.44% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | No |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
TMED Costs Over Time
On $10,000 invested in TMED, assuming 5% a year before costs, total costs come to $278 over 5 years, cutting the return by 0.46% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.44%) | $46 | $145 | $253 |
| Lost growth on money paid in costs | $0 | $7 | $25 |
| Total costs | $46 | $152 | $278 |
| Value after costs | $10,454 | $11,424 | $12,484 |
| Impact on return, per year | 0.46% | 0.46% | 0.46% |
TMED Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 44%
- Securities on loan, average value: $50K
- Net income from securities lending: $217 (0.002% of average net assets)
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.